MDT - Medtronic plc

NYSE - NYSE Delayed Price. Currency in USD
102.76
+1.01 (+0.99%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close101.75
Open102.51
Bid99.93 x 800
Ask102.89 x 800
Day's Range101.92 - 103.04
52 Week Range81.66 - 103.95
Volume4,758,099
Avg. Volume4,789,320
Market Cap137.818B
Beta (3Y Monthly)0.55
PE Ratio (TTM)30.13
EPS (TTM)3.41
Earnings DateAug 20, 2019
Forward Dividend & Yield2.16 (2.12%)
Ex-Dividend Date2019-07-05
1y Target Est105.70
Trade prices are not sourced from all markets
  • Reuters

    UPDATE 1-Edwards Lifesciences, Medtronic heart valves win U.S. approval for expanded use

    Heart valve systems from Edwards Lifesciences Corp and Medtronic Plc have been approved for use in a condition that restricts blood flow from the heart in patients at low-risk of death linked to open-heart surgeries, the U.S. FDA said on Friday. The Food and Drug Administration approved two of Edwards' transcatheter heart valve systems called Sapien 3 And Sapien 3 Ultra as well as Medtronic's Evolut Transcatheter Aortic Valve Replacement (TAVR)system.

  • Medtech Stock Hits Record High On TAVR Nod For Healthier Patients
    Investor's Business Daily

    Medtech Stock Hits Record High On TAVR Nod For Healthier Patients

    Shares of Medtronic and Edwards Lifesciences jumped Friday after the Food and Drug Administration approved their TAVR heart-valve replacement systems for healthier and younger patients.

  • Top Stock Reports for Cisco, Medtronic & Novo Nordisk
    Zacks

    Top Stock Reports for Cisco, Medtronic & Novo Nordisk

    Top Stock Reports for Cisco, Medtronic & Novo Nordisk

  • GlobeNewswire

    Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality

    Medtronic plc (MDT) today announced U.S. Food and Drug Administration (FDA) approval of the Evolut™ Transcatheter Aortic Valve Replacement (TAVR) system for patients with symptomatic severe native aortic stenosis who are at a low risk of surgical mortality. The low-risk patient population is the final surgical risk category to be approved for this minimally invasive alternative to open-heart surgical valve replacement (SAVR) and includes patients who may be younger and more active than higher-risk patients.

  • Medtronic (MDT) to Report Q1 Earnings: What's in Store?
    Zacks

    Medtronic (MDT) to Report Q1 Earnings: What's in Store?

    Medtronic's (MDT) successful execution of growth policies should aid earnings results in the fiscal first quarter.

  • Here's Why You Should Hold Onto Omnicell (OMCL) Stock for Now
    Zacks

    Here's Why You Should Hold Onto Omnicell (OMCL) Stock for Now

    Investor confidence continues to be high on Omnicell's (OMCL) prospects.

  • QIAGEN Posts QIAstat-Dx Gastrointestinal Panel Study Results
    Zacks

    QIAGEN Posts QIAstat-Dx Gastrointestinal Panel Study Results

    The study outcome has been a major step for QIAGEN (QGEN) toward offering accurate diagnosis and treatment of gastroenteritis.

  • Teledyne Technologies, Netgear, Boston Scientific, Medtronic and Becton Dickinson highlighted as Zacks Bull and Bear of the Day
    Zacks

    Teledyne Technologies, Netgear, Boston Scientific, Medtronic and Becton Dickinson highlighted as Zacks Bull and Bear of the Day

    Teledyne Technologies, Netgear, Boston Scientific, Medtronic and Becton Dickinson highlighted as Zacks Bull and Bear of the Day

  • GlobeNewswire

    Medtronic Approved to Start Pivotal Trial to Evaluate New Extended Wear Infusion Set

    Medtronic plc (MDT), the global leader in medical technology, today announced that it received investigational approval from the U.S. Food and Drug Administration (FDA) to proceed with a pivotal trial for a new extended wear infusion set. The goal of the study will be to collect clinical data to support the use of the extended wear infusion set for up to seven days – more than twice the length of time that any infusion set can currently be used. The multi-center, non-randomized, prospective single arm study will enroll up to 150 subjects, aged 18 to 80, with type 1 diabetes on insulin pump therapy.

  • 5 Dependable Dividend Stocks to Buy
    InvestorPlace

    5 Dependable Dividend Stocks to Buy

    If you're like me, the last week or so has made you a bit seasick. Thanks to the escalating trade war, dwindling economic data and perhaps missteps by the Federal Reserve, volatility is rising. Heck, the so-called "fear index" -- the CBOE Volatility Index (VIX) -- has spiked to levels not seen in years. That's making for some nasty swings in the overall market. For many investors, those swings are resulting in plenty of sleepless nights. There's nothing worse than being on the cusp of retirement and having to deal with this volatility.With a hefty dose of dividend stocks, you don't have to.By nature, dividend stocks are generally less volatile than non-dividend stocks. That's because getting 2%-4% in cash helps smooth out returns, no matter what the market is doing. At the same time, in order to continue paying those quarterly checks, dividend stocks tend to be of higher quality, featuring steady revenues, low debt and wide moats. As a result, investors tend to abandon dividend stocks less than non-payers during times of duress and their overall volatility is lower.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 8 Dividend Aristocrat Stocks to Buy Now No Matter What This is exactly where investors should be focusing their attention in the weeks and months ahead. As things get dicier, dividends will help get you through.But which dividend stocks make the cut? Here are five that feature long-term dependability. Dividend Stocks To Buy: Kimberly-Clark (KMB)Source: Trong Nguyen / Shutterstock.com Dividend Yield: 2.95%There's nothing particularly exciting about toilet paper, diapers or tissues. But that doesn't mean that boring can't be profitable. In fact, Kimberly-Clark (NYSE:KMB) has turned purveying paper towels into a cash flow rich niche, and one that has rewarded investors for decades.KMB owns such powerhouse brands as Huggies and Pull-Ups diapers, Kleenex tissues, Scott and Cottonelle toilet paper and Depends undergarment protectors. The firm sells these major brands across more than 175 different countries. And according to the firm's own metrics, 1 in 4 people worldwide use at least one of its products each day. This huge moat and brand penetration have continued to power the firm's revenues over its history. Last quarter, Kimberly-Clark stock managed to see a 5% jump in organic sales year-over-year.That revenue growth may not seem tech-worthy, but with continued improving margins, it's allowed KMB stock to see steadily improving profits. Here again, year-over-year earnings per share for the paper producer grew by 5%. For a steady dividend payer, this is exactly what you want to see -- rising sales and profits that are consistent. And they've been consistent enough to reward shareholders in a big way.Last quarter, KMB managed to hand out $520 million in dividends and buybacks. Management estimates that it'll fork over around $2.3 billion for such activities over the rest of the year. Medtronic (MDT)Source: JHVEPhoto / Shutterstock.com Dividend Yield: 2.13%Forty-two years is a long time. But that's just how long Medtronic (NYSE:MDT) stock has been paying increasing dividends. This puts MDT in an elite group of dividend stocks dubbed the Dividend Aristocrats that have been rewarding investors through thick and thin.Driving that dividend growth is MDT's business model. The firm basically invented the medical devices sector when it created the first artificial heart/pacemaker back in the 1950s. Today, it's one of the largest device markers spanning a variety of cardiovascular, spine, surgery and other products needed by doctors and hospitals. This vast portfolio churns out plenty of steady cash flows and sales. Last quarter alone, Medtronic managed to sell more than $8 billion worth of devices.The best part is that MDT stock has continued to see some big growth as well.The device maker continues to move into higher-margin and more high-tech devices such as advanced diabetes monitors that use artificial intelligence to determine insulin levels. Sales of these devices have been swift. This has improved MDT's profitability profile and helped boost its cash flows further. And MDT has been sharing those cash flows with investors. The firm recently upped its dividend by 8%, following a 9% boost last year. * 7 Safe Dividend Stocks for Investors to Buy Right Now With new devices pulling in high margins and old devices making plenty of steady sales, MDT could be one of the best dividend stocks to buy in this market. Medtronic yields 2.13%. Oracle (ORCL)Source: JHVEPhoto / Shutterstock.com Dividend Yield: 1.8%Truth be told, many investors have forgotten about Oracle (NYSE:ORCL) in favor of smaller, faster-growing tech stocks. That's a real shame as Larry Ellison's baby is still a great firm and increasingly, a wonderful dividend stock.The enterprise software giant has successfully transitioned to the cloud and now offers a variety of database management and other products to meet the needs of businesses. And if it couldn't build it on its own, Ellison has been very successful in buying what it needs. It added cloud-based enterprise resource planning software maker NetSuite in 2016 and construction project management software firm Aconex back in 2017.The transition to the cloud has been successful for Oracle. Over the course of fiscal 2019, ORCL managed to pull in nearly $40 billion in total revenue. However, cloud services and licenses managed to make up 82% of those. Better still, ORCL stock has continued to see improving margins from these operations.This has flooded the firm with cash. At the end of last quarter, ORCL had more than $37 billion in cash and short-term investments on its balance sheet. This gives it plenty of room to buy out additional cloud players and reward shareholders. Since initiating a dividend in 2009, Oracle has managed to grow its payout by 380%. This includes its last 26% boost at the start of the year.For income seekers, ORCL stock shouldn't be ignored. While its 1.8% yield isn't super high, it has the goods to keep its growth over the long haul. Extra Space Storage (EXR)Source: dennizn / Shutterstock.com Dividend Yield: 3%Some of the biggest beneficiaries of the last downturn were the self-storage real estate investment trusts. Americans have a lot of stuff, and as the housing crisis hit, many families were forced to downsize into smaller homes and apartments. That meant finding a place for all their Christmas decorations, family heirlooms and vintage Beanie Babies. This has made Extra Space Storage (NYSE:EXR) a wonderful dividend stock to own over the last few years.That's because for the storage unit owners, it's a game of scale. Most of the sector is owned by mom and pop operators, so giants like Extra Space are able to use their massive size to often price out these operators from the market. Better still, firms like EXR can often offer them attractive buyouts -- which only then improves its own cash flows. Right now, EXR owns nearly 1700 self-storage facilities across the country and continues to smartly add to that pool of assets.That huge pool of facilities continues to work wonders for the firm's cash flows. Since 2006, funds from operations at Extra Space have managed to surge by more than 600%. That beats the pants off its rivals like Public Storage (NYSE:PSA) and CubeSmart (NYSE:CUBE). Rising funds from operations directly translates into bigger dividends. Over the last five years, EXR stock has seen its dividend jump by 91%. * 5 Cheap Stocks to Buy Now That the Fed Cut Rates Given its history of dividend growth during times of stress, EXR could be one of the best dividend stocks as we approach another dicey economic situation. iShares Preferred and Income Securities ETF (PFF)Dividend Yield: 5.3%Perhaps the best way to avoid the stress and volatility of the recent market is to blend the world of dividend stocks and bonds together. We're talking about preferred stocks. Offering steady coupon-like dividend payouts and callable par value, preferred stocks are a naturally lower-volatility choice for portfolios. However, given the low volumes and hard to research nature of the sector, a broad approach is best. And for that, the iShares Preferred and Income Securities ETF (NASDAQ:PFF) is the best choice.With almost $16 billion in assets and nearly 2 million in daily trading volume, PFF is the largest exchange-traded fund tracking the sector. With it's underlying index -- the ICE Exchange-Listed Preferred & Hybrid Securities Index -- tracks more than 470 different preferred stocks. Financials and utilities make up the bulk of holdings, with preferred stocks issued by Bank of America (NYSE:BAC) and NextEra Energy (NYSE:NEE) leading the pack.That huge portfolio of preferred stocks provides plenty of diversification and manages to push out a big 5.3% dividend yield. Even better is that PFF pays that dividend monthly -- an added benefit for those in retirement. Returns for the ETF have mostly been via that dividend, highlighting the stability of owning preferred stocks.With expenses of just 0.46%, or $46 per $10,000 invested, PFF makes a great choice to boost yield, while still owning dividend stocks in the wavy market environment.At the time of writing, Aaron Levitt did not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks Under $5 to Buy for Fall * 5 Stocks to Avoid Amid the Ongoing Trade War * 7 5G Stocks to Buy Now for the Future The post 5 Dependable Dividend Stocks to Buy appeared first on InvestorPlace.

  • FDA Resets PAD Guidelines: The Road Ahead for Device Makers
    Zacks

    FDA Resets PAD Guidelines: The Road Ahead for Device Makers

    On its advisory list, the FDA suggests that doctors should point out the risks and benefits of all available PAD treatment options to their patients.

  • Cardiovascular Systems Set to Present LIBERTY 360 Outcome
    Zacks

    Cardiovascular Systems Set to Present LIBERTY 360 Outcome

    This study outcome is expected to be a major stride forward in Cardiovascular Systems' (CSII) endeavor to offer treatment to patients of multi-level peripheral artery disease (PAD).

  • CVS Health Banks on Health Care Benefit Prospects Amid Woes
    Zacks

    CVS Health Banks on Health Care Benefit Prospects Amid Woes

    CVS Health's (CVS) recently introduced Health Care Benefits segment following the Aetna acquisition is gaining a strong momentum.

  • ResMed (RMD) Hits a New 52-Week High: What's Driving It?
    Zacks

    ResMed (RMD) Hits a New 52-Week High: What's Driving It?

    ResMed (RMD) gains from promising financial results in the fourth quarter of fiscal 2019.

  • Here's Why You Should Hold Onto Insulet (PODD) Stock for Now
    Zacks

    Here's Why You Should Hold Onto Insulet (PODD) Stock for Now

    Investor confidence continues to be high on Insulet's (PODD) solid prospects.

  • Medtronic (MDT) Gains But Lags Market: What You Should Know
    Zacks

    Medtronic (MDT) Gains But Lags Market: What You Should Know

    In the latest trading session, Medtronic (MDT) closed at $102.40, marking a +1.41% move from the previous day.

  • GlobeNewswire

    Medtronic to Announce Financial Results for Its First Quarter of Fiscal Year 2020

    Medtronic plc (MDT) announced today that it will report financial results for the first quarter of fiscal year 2020 on Tuesday, August 20, 2019. The news release will include summary financial information for the company’s first quarter of fiscal year 2020, which ended on Friday, July 26, 2019. Medtronic will host a webcast at 7:00 a.m. CDT to discuss financial results for its first quarter of fiscal year 2020.

  • Medtronic (MDT) Reports Next Week: Wall Street Expects Earnings Growth
    Zacks

    Medtronic (MDT) Reports Next Week: Wall Street Expects Earnings Growth

    Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Boston Scientific Rides on New Products Amid Dull Pacer Sales
    Zacks

    Boston Scientific Rides on New Products Amid Dull Pacer Sales

    Within MedSurg, Boston Scientific (BSX) is on track for the year-end launch of Exalt-D Single-Use Duodenoscope, which is used in ERCP procedures.

  • Baxter (BAX) Hits 52-Week High, Can the Run Continue?
    Zacks

    Baxter (BAX) Hits 52-Week High, Can the Run Continue?

    Baxter (BAX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • Canopy Growth Set to Acquire Beckley Canopy Therapeutics
    Zacks

    Canopy Growth Set to Acquire Beckley Canopy Therapeutics

    With the Beckley Canopy Therapeutics acquisition, Canopy Growth's (CGC) research and development endeavors would be expanding worldwide, thereby making the company a global pioneer in cannabinoid research.

  • Medtronic plc (NYSE:MDT): What Does The Future Look Like?
    Simply Wall St.

    Medtronic plc (NYSE:MDT): What Does The Future Look Like?

    The latest earnings release Medtronic plc's (NYSE:MDT) announced in June 2019 signalled that the company experienced a...

  • Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know
    Zacks

    Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know

    Medtronic (MDT) closed the most recent trading day at $101.39, moving +0.15% from the previous trading session.

  • David Carlson Exits Medtronic, Trims Apple Holding
    GuruFocus.com

    David Carlson Exits Medtronic, Trims Apple Holding

    Guru's largest sales of the 2nd quarter Continue reading...

  • Is Medtronic (MDT) Outperforming Other Medical Stocks This Year?
    Zacks

    Is Medtronic (MDT) Outperforming Other Medical Stocks This Year?

    Is (MDT) Outperforming Other Medical Stocks This Year?